Mimi’s Rock Corp. Shareholders Approve Acquisition by 17-02-2023, 07:25

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer 3-05-2023, 03:05